Metacrine Performance
| MTCRDelisted Stock | USD 0.49 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Metacrine's returns are expected to increase less than the market. However, during the bear market, the loss of holding Metacrine is expected to be smaller as well. Metacrine right now secures a risk of 0.0%. Please verify Metacrine potential upside, as well as the relationship between the kurtosis and market facilitation index , to decide if Metacrine will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Metacrine has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Metacrine is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 24.4 M | |
| Total Cashflows From Investing Activities | 43.9 M |
Metacrine |
Metacrine Relative Risk vs. Return Landscape
If you would invest 49.00 in Metacrine on September 23, 2024 and sell it today you would earn a total of 0.00 from holding Metacrine or generate 0.0% return on investment over 90 days. Metacrine is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Metacrine, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Metacrine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Metacrine's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Metacrine, and traders can use it to determine the average amount a Metacrine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MTCR |
Based on monthly moving average Metacrine is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Metacrine by adding Metacrine to a well-diversified portfolio.
Metacrine Fundamentals Growth
Metacrine Stock prices reflect investors' perceptions of the future prospects and financial health of Metacrine, and Metacrine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Metacrine Stock performance.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.37 | |||
| Current Valuation | (23.98 M) | |||
| Shares Outstanding | 42.57 M | |||
| Price To Book | 0.40 X | |||
| EBITDA | (60.71 M) | |||
| Cash And Equivalents | 55.53 M | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 13.3 M | |||
| Debt To Equity | 0.33 % | |||
| Book Value Per Share | 0.87 X | |||
| Cash Flow From Operations | (47.16 M) | |||
| Earnings Per Share | (1.93) X | |||
| Total Asset | 79.99 M | |||
About Metacrine Performance
Assessing Metacrine's fundamental ratios provides investors with valuable insights into Metacrine's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Metacrine is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Metacrine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Metacrine performance evaluation
Checking the ongoing alerts about Metacrine for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Metacrine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Metacrine is not yet fully synchronised with the market data | |
| Metacrine has some characteristics of a very speculative penny stock | |
| Metacrine has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (62.21 M) with loss before overhead, payroll, taxes, and interest of (45.47 M). | |
| Metacrine currently holds about 55.53 M in cash with (47.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Metacrine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Metacrine's stock is overvalued or undervalued compared to its peers.
- Examining Metacrine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Metacrine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Metacrine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Metacrine's stock. These opinions can provide insight into Metacrine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Metacrine Stock
If you are still planning to invest in Metacrine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Metacrine's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |